Cassava Sciences' Alzheimer's drug, simufilam, has failed in a large clinical trial, proving to be no more effective than a placebo. This outcome is particularly devastating for the nearly 2,000 participants involved, as the drug was based on falsified research and misleading claims. The failure highlights the ongoing challenges in Alzheimer's drug development and the significant time lost for those who participated in the trials.
Cassava Sciences' stock plummeted by 80% in premarket trading after its Alzheimer's drug, Simufilam, failed to show significant efficacy in a late-stage trial. The company announced it would discontinue further studies of the drug, which was intended for mild-to-moderate Alzheimer's patients. This setback follows a $40 million settlement with the SEC over allegations of clinical trial data manipulation.
Cassava Sciences' stock plummeted over 83% after its Alzheimer's drug, simufilam, failed to show significant improvement in patients during Phase 3 trials. This marks the stock's lowest point in over four years, as the treatment did not outperform a placebo in cognitive or functional decline among patients with mild-to-moderate Alzheimer's disease.
Cassava Sciences has completed its Phase 3 RETHINK-ALZ trial for simufilam, an Alzheimer's treatment candidate, with topline data expected by the end of the year.
